Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458861 | 0.91 | FLT1 (0.41) | AURKAABCB1LRRK2ALKEGFR | |
| SCHEMBL5447714 | 0.91 | FLT1 (0.41) | AURKAABCB1LRRK2ALKEGFR | |
| SCHEMBL5444198 | 0.88 | AURKA (0.43) | AURKAEGFRFGFR1FLT1FLT4 | |
| SCHEMBL14564695 | 0.84 | KDR (0.52) | AURKAEGFRFGFR1FLT1FLT4 | |
| SCHEMBL5495618 | 0.79 | RET (0.36) | ALKEGFRFGFR1FLT1FLT4 | |
| SCHEMBL5455019 | 0.79 | EGFR (0.45) | AURKAEGFRFGFR1FLT1FLT4 | |
| SCHEMBL14564692 | 0.75 | KDR (0.61) | EGFRFGFR1FLT1FLT4KDR | |
| SCHEMBL14564693 | 0.74 | KDR (0.60) | EGFRFGFR1FLT1FLT4KDR | |
| SCHEMBL27593927 | 0.73 | KDM4E (0.41) | AURKAABCB1EGFR | |
| SCHEMBL14564694 | 0.71 | EGFR (0.57) | AURKAEGFRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | claimed |
| EP-1274692-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | claimed |
| US-20030191308-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | US | claimed |
| US-20070066633-A1 | Quinazoline compounds | ASTRAZENECA AB | 2007-03-22 | — | — | US | disclosed |
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| EP-1274692-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20030191308-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | US | disclosed |
| EP-1274692-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001077085-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191308-A1 | Quinazoline compounds | CNR1, CBR1, CCR7 | AURKA 3083/4885ABCB1 429/4885LRRK2 4779/4885 |
| US-20070066633-A1 | Quinazoline compounds | CCR7, CNR1, CBR3 | AURKA 2327/4885ABCB1 478/4885LRRK2 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.